"Zach Reitano has helped scale Ro into a leading provider of branded GLP-1s, gaining attention with a Super Bowl ad featuring tennis champion Serena Williams and a partnership with Novo Nordisk."
"Reitano acknowledges the challenges ahead, including the long-term health unknowns of GLP-1 medications and the cultural backlash surrounding the term 'Ozempic face.'"
"The decision to invest in a Super Bowl ad was influenced by the need for brand visibility, despite initial hesitations about advertising in a market with sufficient supply."
Zach Reitano, CEO of Ro, has successfully positioned his company as a leader in the GLP-1 market, particularly with the medications Ozempic, Wegovy, and Zepbound. The company gained significant visibility through a Super Bowl ad featuring Serena Williams and a partnership with Novo Nordisk for Wegovy's pill version. However, Reitano faces challenges including the long-term health implications of these medications and societal reactions to their use. The evolving landscape of healthcare and pharmaceuticals is also a concern as the popularity of these drugs continues to rise.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]